Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | KAT8 | Q9H7Z6 | 4/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25318818 | 0.94 | DRD2 (0.44) | BTKKMT2AL3MBTL1MAOBMAOA | |
| SCHEMBL965092 | 0.94 | DRD2 (0.44) | BTKKMT2AL3MBTL1MAOBMAOA | |
| SCHEMBL6642035 | 0.94 | DRD2 (0.44) | BTKKMT2AL3MBTL1MAOBMAOA | |
| SCHEMBL27228950 | 0.90 | MAOB (0.43) | BTKKMT2AL3MBTL1TSHRMAOB | |
| SCHEMBL27232496 | 0.90 | MAOB (0.43) | BTKKMT2AL3MBTL1TSHRMAOB | |
| SCHEMBL942085 | 0.87 | DRD2 (0.46) | KMT2AL3MBTL1MAOBMAOAADORA3 | |
| SCHEMBL942084 | 0.87 | DRD2 (0.46) | KMT2AL3MBTL1MAOBMAOAADORA3 | |
| SCHEMBL9885083 | 0.87 | DRD2 (0.46) | KMT2AL3MBTL1MAOBMAOAADORA3 | |
| SCHEMBL25271793 | 0.83 | BTK (0.49) | BTKKMT2AL3MBTL1TSHRMAOB | |
| SCHEMBL16899708 | 0.83 | BTK (0.49) | BTKKMT2AL3MBTL1TSHRMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459922-B2 | PARP7 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250100998-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2025-03-27 | — | — | US | disclosed |
| WO-2025024811-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| EP-4469448-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250100998-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | BTK 1242/4885KMT2A 821/4885L3MBTL1 3326/4885 |
| US-12459922-B2 | PARP7 inhibitors | PARP1, PARP11, PARP2 | BTK 1242/4885KMT2A 821/4885L3MBTL1 3326/4885 |
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | BTK 1242/4885KMT2A 821/4885L3MBTL1 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.